1. Home
  2. VALU vs CAPR Comparison

VALU vs CAPR Comparison

Compare VALU & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Value Line Inc.

VALU

Value Line Inc.

N/A

Current Price

$37.48

Market Cap

340.4M

Sector

Finance

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$26.81

Market Cap

324.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VALU
CAPR
Founded
1931
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
340.4M
324.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VALU
CAPR
Price
$37.48
$26.81
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$32.14
AVG Volume (30 Days)
3.1K
5.7M
Earning Date
12-15-2025
11-10-2025
Dividend Yield
3.47%
N/A
EPS Growth
6.17
N/A
EPS
2.26
N/A
Revenue
$34,801,000.00
$11,130,509.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,736.03
P/E Ratio
$16.61
N/A
Revenue Growth
N/A
N/A
52 Week Low
$32.94
$4.30
52 Week High
$55.01
$40.37

Technical Indicators

Market Signals
Indicator
VALU
CAPR
Relative Strength Index (RSI) 51.16 79.98
Support Level $36.50 $4.30
Resistance Level $38.60 $40.37
Average True Range (ATR) 0.74 2.60
MACD 0.17 2.56
Stochastic Oscillator 52.29 62.78

Price Performance

Historical Comparison
VALU
CAPR

About VALU Value Line Inc.

Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: